Article Sidebar

PDF
Date Published: 25/04/2022
Abstract Views: 238
Views PDF: 196
DOI: https://doi.org/10.51298/vmj.v512i1.2236
Issue
Vol. 512 No. 1 (2022)
Section
Các bài báo
How to Cite
Minh Hà, T. ., & Thị Lâm Hường, Đào . (2022). EVALUATE CHANGES IN VISUAL FIELD OF EYES WITH PRIMARY OPEN ANGLE GLAUCOMA AFTER SELECTIVE LASER TRABECULOPLASTY. Vietnam Medical Journal, 512(1). https://doi.org/10.51298/vmj.v512i1.2236

EVALUATE CHANGES IN VISUAL FIELD OF EYES WITH PRIMARY OPEN ANGLE GLAUCOMA AFTER SELECTIVE LASER TRABECULOPLASTY

Trần Minh Hà1,, Đào Thị Lâm Hường2
1 Alina Eye Hospital
2 Vietnam Ophthalmological Society

Main Article Content

Abstract

Objective: Evaluate changes in visual field of eyes with primary open angle glaucoma after selective laser trabeculoplasty (SLT). Subjects and Methods: A prospective, randomised clinical trial. 84 eyes with POAG were randomised to receive Travoprost 0,004% 1 time at night or 360˚SLT. Humphrey visual field 24:2 test was evaluated at baseline, 6 month, 12 month and 18 month. Results: After 18 months, means and median of MD and PSD was no statistical different. 37 eyes (88,0%) in SLT group have visual field slow improvement while 2 eyes (4,8%) have slow progression, 1 eye (2,4%) has moderate progression and 2 eyes (4,8%) have fast progression. No eye progressed to higher stage of visual field defect. Travoprost 0,004% group has higher rate of fast progression than SLT group (11,9% vs 4,8%), however there is no statistical difference with p>0.05. Conclusion: Eyes with primary open angle glaucoma have stable visual field after selective laser trabeculoplasty and no statistical difference in propostion of eyes that progress between two treatment groups.

Article Details

Keywords

Primary open angle glaucoma, visual field progression, selective laser trabeculoplasty

References

1. Bryan SR, Crabb DP. A New Graphical Tool for Assessing Visual Field Progression in Clinical Populations. Transl Vis Sci Technol. Feb 2018;7(1):22.
2. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. Apr 13 2019;393(10180):1505-1516.
3. Jang Y, Jee D, Lee D, Choi NK, Bae S. Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data. Int J Environ Res Public Health. Apr 13 2021;18(8)
4. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. Apr 1995;60(4):359-71.
5. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. Sep 2004;111(9):1627-35.
6. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. Jan 1998;105(1):82-7.
7. Wong MO, Lee JW, Choy BN, Chan JC, Lai JS. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. Jan-Feb 2015;60(1):36-50.
8. Wright DM, Konstantakopoulou E, Montesano G, et al. Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT). Ophthalmology. Oct 2020;127(10):1313-1321.